| 5.94 0.06 (1.02%) | 02-03 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 7.4 | 1-year : | 8.64 |
| Resists | First : | 6.34 | Second : | 7.4 |
| Pivot price | 5.45  |
|||
| Supports | First : | 5.34 | Second : | 4.73 |
| MAs | MA(5) : | 5.66 |
MA(20) : | 5.38 |
| MA(100) : | 5.84  |
MA(250) : | 6.23 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 85 |
D(3) : | 76.4 |
| RSI | RSI(14): 60 |
|||
| 52-week | High : | 8.27 | Low : | 4.34 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AURA ] has closed below upper band by 10.2%. Bollinger Bands are 23.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.13 - 6.15 | 6.15 - 6.17 |
| Low: | 5.78 - 5.81 | 5.81 - 5.83 |
| Close: | 5.9 - 5.93 | 5.93 - 5.97 |
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Sun, 01 Feb 2026
Discipline and Rules-Based Execution in AURA Response - Stock Traders Daily
Sat, 31 Jan 2026
Guidance Update: Can Aura Biosciences Inc deliver alpha - Trade Entry Report & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Fri, 23 Jan 2026
Following a 29% decline over last year, recent gains may please Aura Biosciences, Inc. (NASDAQ:AURA) institutional owners - simplywall.st
Thu, 22 Jan 2026
We're Keeping An Eye On Aura Biosciences' (NASDAQ:AURA) Cash Burn Rate - Yahoo Finance
Wed, 21 Jan 2026
Aura Biosciences SVP Amy Elazzouzi sells $7683 in stock By Investing.com - Investing.com Nigeria
Tue, 20 Jan 2026
Top Executive Makes a Big Move With Aura Biosciences Stock - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 64 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 1.8 (%) |
| Held by Institutions | 82.3 (%) |
| Shares Short | 3,190 (K) |
| Shares Short P.Month | 3,060 (K) |
| EPS | -1.91 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.49 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -35.9 % |
| Return on Equity (ttm) | -64.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.77 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -88 (M) |
| Levered Free Cash Flow | -51 (M) |
| PE Ratio | -3.11 |
| PEG Ratio | 0 |
| Price to Book value | 2.38 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|